Oxford BioDynamics Plc (OBD), a biotechnology company developing precision medicine tests for immune health, has announced the grant of 2,500,500 share options over its ordinary shares to Group employees, including certain directors and persons discharging managerial responsibilities (PDMRs) of the company. The options were granted under the 2016 Employee Share Option Plan and have an exercise price of 34p per share. The options will vest in three equal tranches on the first, second, and third anniversaries of the grant date and will remain exercisable up to the tenth anniversary of the grant date.

The individuals who have been granted options and their respective holdings are as follows: Alexandre Akoulitchev, Chief Scientific Officer (1,596,131 options and 6,603,082 ordinary shares); Paul Stockdale, Chief Financial Officer (1,050,000 options and 331,818 ordinary shares); Matthew Wakefield, Non-Executive Chairman (400,000 options and 1,022,727 ordinary shares); David Holbrook, Non-Executive Director (115,000 options); David Blum, SVP of Marketing (462,500 options and 75,000 ordinary shares); Thomas Guiel, Chief Operations Officer (650,000 options and 365,000 ordinary shares); and Ewan Hunter, Chief Data Officer (750,000 options and 136,363 ordinary shares).

The notifications made in accordance with the UK Market Abuse Regulation provide further details of the transactions. The share options were granted on 20 October 2023 outside a trading venue.